Judith M. Hönes
University of Duisburg-Essen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Judith M. Hönes.
Leukemia | 2016
Judith M. Hönes; Lacramioara Botezatu; A Helness; Charles Vadnais; L Vassen; François Robert; S M Hergenhan; Aniththa Thivakaran; J Schütte; Yahya S. Al-Matary; Robert F. Lams; J Fraszscak; Hideki Makishima; Tomas Radivoyevitch; Bartlomiej Przychodzen; S V da Conceição Castro; André Görgens; Bernd Giebel; L Klein-Hitpass; K Lennartz; Michael Heuser; Christian Thiede; Gerhard Ehninger; Ulrich Dührsen; Jaroslaw P. Maciejewski; Tarik Möröy; C Khandanpour
Genetic and epigenetic aberrations contribute to the initiation and progression of acute myeloid leukemia (AML). GFI1, a zinc-finger transcriptional repressor, exerts its function by recruiting histone deacetylases to target genes. We present data that low expression of GFI1 is associated with an inferior prognosis of AML patients. To elucidate the mechanism behind this, we generated a humanized mouse strain with reduced GFI1 expression (GFI1-KD). Here we show that AML development induced by onco-fusion proteins such as MLL-AF9 or NUP98-HOXD13 is accelerated in mice with low human GFI1 expression. Leukemic cells from animals that express low levels of GFI1 show increased H3K9 acetylation compared to leukemic cells from mice with normal human GFI1 expression, resulting in the upregulation of genes involved in leukemogenesis. We investigated a new epigenetic therapy approach for this subgroup of AML patients. We could show that AML blasts from GFI1-KD mice and from AML patients with low GFI1 levels were more sensitive to treatment with histone acetyltransferase inhibitors than cells with normal GFI1 expression levels. We suggest therefore that GFI1 has a dose-dependent role in AML progression and development. GFI1 levels are involved in epigenetic regulation, which could open new therapeutic approaches for AML patients.
Haematologica | 2016
Yahya S. Al-Matary; Lacramioara Botezatu; Bertram Opalka; Judith M. Hönes; Robert F. Lams; Aniththa Thivakaran; Judith Schütte; Renata Köster; Klaus Lennartz; Thomas Schroeder; Rainer Haas; Ulrich Dührsen; Cyrus Khandanpour
The growth of malignant cells is not only driven by cell-intrinsic factors, but also by the surrounding stroma. Monocytes/Macrophages play an important role in the onset and progression of solid cancers. However, little is known about their role in the development of acute myeloid leukemia, a malignant disease characterized by an aberrant development of the myeloid compartment of the hematopoietic system. It is also unclear which factors are responsible for changing the status of macrophage polarization, thus supporting the growth of malignant cells instead of inhibiting it. We report herein that acute myeloid leukemia leads to the invasion of acute myeloid leukemia-associated macrophages into the bone marrow and spleen of leukemic patients and mice. In different leukemic mouse models, these macrophages support the in vitro expansion of acute myeloid leukemia cell lines better than macrophages from non-leukemic mice. The grade of macrophage infiltration correlates in vivo with the survival of the mice. We found that the transcriptional repressor Growth factor independence 1 is crucial in the process of macrophage polarization, since its absence impedes macrophage polarization towards a leukemia supporting state and favors an anti-tumor state both in vitro and in vivo. These results not only suggest that acute myeloid leukemia-associated macrophages play an important role in the progression of acute myeloid leukemia, but also implicate Growth factor independence 1 as a pivotal factor in macrophage polarization. These data may provide new insights and opportunities for novel therapies for acute myeloid leukemia.
Scientific Reports | 2017
Judith M. Hönes; Aniththa Thivakaran; Lacramioara Botezatu; Pradeep Patnana; Symone Vitorianoda Conceição Castro; Yahya S. Al-Matary; Judith Schütte; Karen Fischer; Lothar Vassen; André Görgens; Ulrich Dührsen; Bernd Giebel; Cyrus Khandanpour
The differentiation of haematopoietic cells is regulated by a plethora of so-called transcription factors (TFs). Mutations in genes encoding TFs or graded reduction in their expression levels can induce the development of various malignant diseases such as acute myeloid leukaemia (AML). Growth Factor Independence 1 (GFI1) is a transcriptional repressor with key roles in haematopoiesis, including regulating self-renewal of haematopoietic stem cells (HSCs) as well as myeloid and lymphoid differentiation. Analysis of AML patients and different AML mouse models with reduced GFI1 gene expression levels revealed a direct link between low GFI1 protein level and accelerated AML development and inferior prognosis. Here, we report that upregulated expression of GFI1 in several widely used leukemic cell lines inhibits their growth and decreases the ability to generate colonies in vitro. Similarly, elevated expression of GFI1 impedes the in vitro expansion of murine pre-leukemic cells. Using a humanized AML model, we demonstrate that upregulation of GFI1 expression leads to myeloid differentiation morphologically and immunophenotypically, increased level of apoptosis and reduction in number of cKit+ cells. These results suggest that increasing GFI1 level in leukemic cells with low GFI1 expression level could be a therapeutic approach.
Haematologica | 2018
Aniththa Thivakaran; Lacramioara Botezatu; Judith M. Hönes; Judith Schütte; Lothar Vassen; Yahya S. Al-Matary; Pradeep Patnana; Amos Zeller; Michael Heuser; Felicitas Thol; Razif Gabdoulline; Nadine Olberding; Daria Frank; Marina Suslo; Renata Köster; Klaus Lennartz; André Görgens; Bernd Giebel; Bertram Opalka; Ulrich Dührsen; Cyrus Khandanpour
Differentiation of hematopoietic stem cells is regulated by a concert of different transcription factors. Disturbed transcription factor function can be the basis of (pre)malignancies such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Growth factor independence 1b (Gfi1b) is a repressing transcription factor regulating quiescence of hematopoietic stem cells and differentiation of erythrocytes and platelets. Here, we show that low expression of Gfi1b in blast cells is associated with an inferior prognosis of MDS and AML patients. Using different models of human MDS or AML, we demonstrate that AML development was accelerated with heterozygous loss of Gfi1b, and latency was further decreased when Gfi1b was conditionally deleted. Loss of Gfi1b significantly increased the number of leukemic stem cells with upregulation of genes involved in leukemia development. On a molecular level, we found that loss of Gfi1b led to epigenetic changes, increased levels of reactive oxygen species, as well as alteration in the p38/Akt/FoXO pathways. These results demonstrate that Gfi1b functions as an oncosuppressor in MDS and AML development.
Haematologica | 2018
Anna E. Marneth; Lacramioara Botezatu; Judith M. Hönes; Jimmy C.L. Israël; Judith Schütte; Lothar Vassen; Robert F. Lams; Saskia M. Bergevoet; Laura Groothuis; Amit Mandoli; Joost H.A. Martens; Gerwin Huls; Joop H. Jansen; Ulrich Dührsen; Tobias Berg; Tarik Möröy; Christian Wichmann; Mia-Chia Lo; Dong-Er Zhang; Bert A. van der Reijden; Cyrus Khandanpour
Author(s): Marneth, Anna E; Botezatu, Lacramioara; Hones, Judith M; Israel, Jimmy CL; Schutte, Judith; Vassen, Lothar; Lams, Robert F; Bergevoet, Saskia M; Groothuis, Laura; Mandoli, Amit; Martens, Joost HA; Huls, Gerwin; Jansen, Joop H; Duhrsen, Ulrich; Berg, Tobias; Moroy, Tarik; Wichmann, Christian; Lo, Mia-Chia; Zhang, Dong-Er; van der Reijden, Bert A; Khandanpour, Cyrus
Experimental Hematology | 2016
Lacramioara Botezatu; Lars C. Michel; Anne Helness; Charles Vadnais; Hideki Makishima; Judith M. Hönes; François Robert; Lothar Vassen; Aniththa Thivakaran; Yahya S. Al-Matary; Robert F. Lams; Judith Schütte; Bernd Giebel; André Görgens; Michael Heuser; Hind Medyouf; Jaroslaw P. Maciejewski; Ulrich Dührsen; Tarik Möröy; Cyrus Khandanpour
Experimental Hematology | 2014
Lars C. Michel; Lacramioara Botezatu; Judith M. Hönes; Damien Grapton; Charles Vadnais; Ulrich Germing; Thomas Schroeder; Rainer Haas; Uwe Platzbecker; Gerhard Ehninger; Hideki Makishima; A E Marneth; Jaroslaw P. Maciejewski; Tarik Möröy; Bert A. van der Reijden; Ulrich Duehrsen; Cyrus Khandanpour
Experimental Hematology | 2014
Judith M. Hönes; Lacramioara Botezatu; Lars C. Michel; Christian Thiede; Bert A. van der Reijden; Michael Heuser; Bob Löwenberg; Hideki Makishima; Gerhard Ehninger; Ulrich Duehrsen; Jaroslaw P. Maciejewski; Tarik Möröy; Cyrus Khandanpour
Blood | 2014
Judith M. Hönes; Lacramioara Botezatu; Lars C. Michel; Christian Thiede; Bert A. van der Reijden; Michael Heuser; Hideki Makishima; Jaroslaw P. Maciejewski; Tomas Radiovoyevitch; Gerhard Ehninger; Ulrich Dührsen; Tarik Möröy; Cyrus Khandanpour
Blood | 2014
Lars C. Michel; Lacramioara Botezatu; Judith M. Hönes; Anna Marneth; Damien Grapton; Charles Vadnais; Ulrich Germing; Uwe Platzbecker; Thomas Schroeder; Rainer Haas; Bert A. van der Reijden; Gerhard Ehninger; Jaroslaw P. Maciejewski; Tomas Radivoyevitch; André Görgens; Bernd Giebel; Jan Fleckhaus; Hideki Makishima; Tarik Möröy; Ulrich Dührsen; Cyrus Khandanpour